NCT00895713View on ClinicalTrials.gov

Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

July 31, 2005

Conditions
Hepatitis B, Chronic
Interventions
DRUG

intramuscular hepatitis B virus immune globulin

Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months

Trial Locations (2)

Unknown

Cisanello Hospital. (University of Pisa)., Pisa

Ospedaliera Molinette, Torino

All Listed Sponsors
lead

Instituto Grifols, S.A.

INDUSTRY

NCT00895713 - Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation | Biotech Hunter | Biotech Hunter